Sharechat Logo

Biotech investors 'had it coming'

By Chris Hutching

Friday 21st March 2003

Text too small?
Australian-based Celentis chief executive officer Stewart Washer says the exodus of investors from the biotech sharemarket is a good thing because share prices are now at a realistic level.

"Most stock valuations currently aren't out of whack and there's a greater than even chance that the biotech dealmaking engine might splutter back to life with a vengeance," he told the Commercialising Biotechnology Conference in Auckland this week.

"What we can reasonably expect is a wave of mergers and acquisitions to strengthen investor confidence in the sector," he said.

"Just in case some of you big spenders out there would like to take your wallets out and spend up large, some of the once-hot names now trading below cash value include Celera Genomics, Transkaryotic Therapies, Incyte Genomics, Sequenom and Curagen.

"Indeed, there was much market speculation only a couple of weeks ago when Wrightson snared just over 15% of Genesis at much below Genesis' cash value if the company was wound up today.

But the biggest recent news was the impending merger of Pfizer and Pharmacia Corp. "It effectively creates a new model for US drug companies."

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

NZ dollar becalmed on US-China trade/politics nexus
Govt to pull Infrastructure Commission into Auckland port imbroglio
Wind to displace diesel for Stewart Island power
Eroad's five year target: doubling unit sales
Blinky boxes and gobbledegook: tips for choosing a cyber-security vendor
Govt support for NZME/Stuff merger difficult, not impossible, says Jarden
NZ dollar stalled; US-China trade signals remain mixed
Ryman warns NZ, Australia to take population ageing more seriously
MARKET CLOSE: NZ shares fall as US-China trade concerns weigh on markets; Ryman slips
NZ dollar stalled; US-China trade deal may be postponed

IRG See IRG research reports